Synopsis Dorzagliatin is a new, dual-acting, allosteric glucokinase activator that targets both pancreatic and hepatic glucokinases and provides effective 24-h glycemic control and improves glucose sensitivity in patients with type 2 diabetes. The present study aims to evaluate the efficacy and safety of dorzagliatin monotherapy at different doses in patients with type 2 diabetes. This week’s “ MED FACT ” discusses a clinical study from The Lancet Diabetes & Endocrinology, “ Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study ”. May 2018.
Authors : Dalong Zhu; Shenglian Gan; Yu Liu; et al. Key Takeaways: Dorzagliatin reduces HbA1c in a dose-dependent manner over 12 weeks of treatment in patients with type 2 diabetes. Objective: To evaluate the efficacy and safety of dorzagliatin monotherapy at…
